{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:53:51Z","timestamp":1785761631940,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Gerontol Geriat"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00391-026-02605-x","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:43:00Z","timestamp":1783507380000},"page":"435-442","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anabole Therapie bei geriatrischen Patient:Innen mit Osteoporose","Anabolic treatment in geriatric patients with osteoporosis"],"prefix":"10.1007","volume":"59","author":[{"given":"Judith","family":"Haschka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"issue":"1","key":"2605_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-020-0706-y","volume":"15","author":"F Borgstrom","year":"2020","unstructured":"Borgstrom\u00a0F, Karlsson\u00a0L, Ortsater\u00a0G, Norton\u00a0N, Halbout\u00a0P, Cooper\u00a0C et\u00a0al (2020) Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos 15(1):59\u201359","journal-title":"Arch Osteoporos"},{"issue":"5","key":"2605_CR2","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1016\/S2468-2667(17)30046-4","volume":"2","author":"N Papadimitriou","year":"2017","unstructured":"Papadimitriou\u00a0N, Tsilidis\u00a0KK, Orfanos\u00a0P, Benetou\u00a0V, Ntzani\u00a0EE, Soerjomataram\u00a0I et\u00a0al (2017) Burden of hip fracture using disability-adjusted life-years: a pooled analysis of prospective cohorts in the CHANCES consortium. Lancet Public Health 2(5):e239\u2013e246","journal-title":"Lancet Public Health"},{"issue":"1","key":"2605_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-75568-x","volume":"14","author":"A Sokhan","year":"2024","unstructured":"Sokhan\u00a0A, Haschka\u00a0J, Reichardt\u00a0B, Zwerina\u00a0J, Kocijan\u00a0R, Behanova\u00a0M (2024) Epidemiological characteristics and impact of sepsis on survival after osteoporotic pelvic fracture in Austria. Sci Rep 14(1):24531","journal-title":"Sci Rep"},{"issue":"2","key":"2605_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00198-020-05557-z","volume":"32","author":"E McCloskey","year":"2021","unstructured":"McCloskey\u00a0E, Rathi\u00a0J, Heijmans\u00a0S, Blagden\u00a0M, Cortet\u00a0B, Czerwinski\u00a0E et\u00a0al (2021) The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study. Osteoporos Int 32(2):251\u2013259","journal-title":"Osteoporos Int"},{"issue":"19","key":"2605_CR5","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer\u00a0RM, Arnaud\u00a0CD, Zanchetta\u00a0JR, Prince\u00a0R, Gaich\u00a0GA, Reginster\u00a0JY et\u00a0al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434\u20131441","journal-title":"N Engl J Med"},{"issue":"10117","key":"2605_CR6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler\u00a0DL, Marin\u00a0F, Zerbini\u00a0CAF, Russo\u00a0LA, Greenspan\u00a0SL, Zikan\u00a0V et\u00a0al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391(10117):230\u2013240","journal-title":"Lancet"},{"issue":"7","key":"2605_CR7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller\u00a0PD, Hattersley\u00a0G, Riis\u00a0BJ, Williams\u00a0GC, Lau\u00a0E, Russo\u00a0LA et\u00a0al (2016) Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA 316(7):722\u2013733","journal-title":"JAMA"},{"issue":"8","key":"2605_CR8","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1210\/jc.2018-00163","volume":"103","author":"HG Bone","year":"2018","unstructured":"Bone\u00a0HG, Cosman\u00a0F, Miller\u00a0PD, Williams\u00a0GC, Hattersley\u00a0G, Hu\u00a0MY et\u00a0al (2018) ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. J\u00a0Clin Endocrinol Metab 103(8):2949\u20132957","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"2605_CR9","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman\u00a0F, Crittenden\u00a0DB, Adachi\u00a0JD, Binkley\u00a0N, Czerwinski\u00a0E, Ferrari\u00a0S et\u00a0al (2016) Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med 375(16):1532\u20131543","journal-title":"N Engl J Med"},{"issue":"15","key":"2605_CR10","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag\u00a0KG, Petersen\u00a0J, Brandi\u00a0ML, Karaplis\u00a0AC, Lorentzon\u00a0M, Thomas\u00a0T et\u00a0al (2017) Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med 377(15):1417\u20131427","journal-title":"N Engl J Med"},{"issue":"02","key":"2605_CR11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/a-2034-6086","volume":"32","author":"PKP Schmidmaier","year":"2023","unstructured":"Schmidmaier\u00a0PKP, Drey\u00a0M, Jakob\u00a0F, Thomasius\u00a0FRH (2023of) Recommendations for the Pharmacological Treatment of Osteoporosis - Update 2023 of the German Osteoporosis Guideline TT - Empfehlungen zur spezifischen medikament\u00f6sen Therapie der Osteoporose - Update 2023 der DVO-Leitlinie. Osteol 32(02):115\u2013122","journal-title":"Osteol"},{"issue":"Suppl 16","key":"2605_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00508-024-02441-2","volume":"136","author":"HP Dimai","year":"2024","unstructured":"Dimai\u00a0HP, Muschitz\u00a0C, Amrein\u00a0K, Bauer\u00a0R, Cejka\u00a0D, Gasser\u00a0RW et\u00a0al (2024) Osteoporosis-Definition, risk assessment, diagnosis, prevention and treatment (update 2024) : Guidelines of the Austrian Society for Bone and Mineral Research. Wien Klin Wochenschr 136(Suppl 16):599\u2013668","journal-title":"Wien Klin Wochenschr"},{"issue":"8","key":"2605_CR13","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1210\/jc.2006-0190","volume":"91","author":"JS Finkelstein","year":"2006","unstructured":"Finkelstein\u00a0JS, Leder\u00a0BZ, Burnett\u00a0SM, Wyland\u00a0JJ, Lee\u00a0H, de la Paz\u00a0AV et\u00a0al (2006) Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J\u00a0Clin Endocrinol Metab 91(8):2882\u20132887","journal-title":"J Clin Endocrinol Metab"},{"key":"2605_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2025.117389","volume":"193","author":"K Ebina","year":"2025","unstructured":"Ebina\u00a0K, Kobayakawa\u00a0T, Etani\u00a0Y, Noguchi\u00a0T, Kashii\u00a0M, Okamura\u00a0G et\u00a0al (2025) Impact of prior teriparatide treatment on the effectiveness of romosozumab in patients with postmenopausal osteoporosis: A case-control study. Bone 193:117389","journal-title":"Bone"},{"issue":"5","key":"2605_CR15","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/j.1532-5415.2006.00695.x","volume":"54","author":"S Boonen","year":"2006","unstructured":"Boonen\u00a0S, Marin\u00a0F, Mellstrom\u00a0D, Xie\u00a0L, Desaiah\u00a0D, Krege\u00a0JH et\u00a0al (2006) Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J\u00a0Am Geriatr Soc 54(5):782\u2013789","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"2605_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00223-012-9590-9","volume":"90","author":"JB Walsh","year":"2012","unstructured":"Walsh\u00a0JB, Lems\u00a0WF, Karras\u00a0D, Langdahl\u00a0BL, Ljunggren\u00a0O, Fahrleitner-Pammer\u00a0A et\u00a0al (2012) Effectiveness of Teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 90(5):373\u2013383","journal-title":"Calcif Tissue Int"},{"key":"2605_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2019.100217","volume":"11","author":"K Shigenobu","year":"2019","unstructured":"Shigenobu\u00a0K, Hashimoto\u00a0T, Kanayama\u00a0M, Ohha\u00a0H, Yamane\u00a0S (2019) The efficacy of osteoporotic treatment in patients with new spinal vertebral compression fracture pain, ADL, QOL, bone metabolism and fracture-healing - In comparison with weekly teriparatide with bisphosphonate. Bone Rep 11:100217","journal-title":"Bone Rep"},{"key":"2605_CR18","doi-asserted-by":"crossref","unstructured":"Kim YH, Ha KY, Bae HW, Park HY, Ko YI, Ko MS, et\u00a0al. The Effects of Longer Use of Teriparatide on Clinical and Radiographic Outcomes after Spinal Fusion in Geriatric Patients. Medicina (Kaunas). 2024;60(6).","DOI":"10.3390\/medicina60060946"},{"issue":"8","key":"2605_CR19","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s00198-024-07059-8","volume":"35","author":"M Chandran","year":"2024","unstructured":"Chandran\u00a0M, Akesson\u00a0KE, Javaid\u00a0MK, Harvey\u00a0N, Blank\u00a0RD, Brandi\u00a0ML et\u00a0al (2024) Impact of osteoporosis and osteoporosis medications on fracture healing: a narrative review. Osteoporos Int 35(8):1337\u20131358","journal-title":"Osteoporos Int"},{"issue":"12","key":"2605_CR20","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s40265-017-0780-7","volume":"77","author":"S Abaloparatide","year":"2017","unstructured":"Abaloparatide\u00a0S (2017) First Global Approval. Drugs 77(12):1363\u20131368","journal-title":"Drugs"},{"issue":"5","key":"2605_CR21","volume":"9","author":"SH Tella","year":"2017","unstructured":"Tella\u00a0SH, Kommalapati\u00a0A, Correa\u00a0R (2017) Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis. Cureus 9(5):e1300","journal-title":"Cureus"},{"issue":"10","key":"2605_CR22","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1097\/GME.0000000000001593","volume":"27","author":"SL Greenspan","year":"2020","unstructured":"Greenspan\u00a0SL, Fitzpatrick\u00a0LA, Mitlak\u00a0B, Wang\u00a0Y, Harvey\u00a0NC, Deal\u00a0C et\u00a0al (2020) Abaloparatide followed by alendronate in women \u3009\/=80\u00a0years with osteoporosis: post hoc analysis of ACTIVExtend. Menopause 27(10):1137\u20131142","journal-title":"Menopause"},{"issue":"13","key":"2605_CR23","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.2106\/JBJS.23.01334","volume":"106","author":"NP Sheth","year":"2024","unstructured":"Sheth\u00a0NP, Smith\u00a0JR, Winzenrieth\u00a0R, Humbert\u00a0L, Wang\u00a0Y, Boxberger\u00a0JI et\u00a0al (2024) Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis. J\u00a0Bone Joint Surg Am 106(13):1162\u20131170","journal-title":"J Bone Joint Surg Am"},{"key":"2605_CR24","first-page":"1","volume":"31","author":"Evenity-Bewertungsbericht EAAfHC","year":"2020","unstructured":"Evenity-Bewertungsbericht EAAfHC (2020) 2020 31:1\u2013263","journal-title":"2020"},{"issue":"3","key":"2605_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/jsp2.1356","volume":"7","author":"K Ishikawa","year":"2024","unstructured":"Ishikawa\u00a0K, Tani\u00a0S, Toyone\u00a0T, Tsuchiya\u00a0K, Towatari\u00a0T, Oshita\u00a0Y et\u00a0al (2024) The potential effect of romosozumab on perioperative management for instrumentation surgery. JOR Spine 7(3):e1356","journal-title":"JOR Spine"},{"key":"2605_CR26","unstructured":"Arzneimittelagentur E. 2026."},{"issue":"2","key":"2605_CR27","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/jbmr.4188","volume":"36","author":"A Gilsenan","year":"2021","unstructured":"Gilsenan\u00a0A, Midkiff\u00a0K, Harris\u00a0D, Kellier-Steele\u00a0N, McSorley\u00a0D, Andrews\u00a0EB (2021) Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study. J\u00a0Bone Miner Res 36(2):244\u2013251","journal-title":"J Bone Miner Res"},{"key":"2605_CR28","unstructured":"1\u201116. ELaCF-fpip."},{"issue":"5","key":"2605_CR29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11914-023-00810-w","volume":"21","author":"JH Tobias","year":"2023","unstructured":"Tobias\u00a0JH (2023) Sclerostin and Cardiovascular Disease. Curr Osteoporos Rep 21(5):519\u2013526","journal-title":"Curr Osteoporos Rep"}],"container-title":["Zeitschrift f\u00fcr Gerontologie und Geriatrie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00391-026-02605-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00391-026-02605-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00391-026-02605-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:23:31Z","timestamp":1785759811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00391-026-02605-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2605"],"URL":"https:\/\/doi.org\/10.1007\/s00391-026-02605-x","relation":{},"ISSN":["0948-6704","1435-1269"],"issn-type":[{"value":"0948-6704","type":"print"},{"value":"1435-1269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J\n                      .\u00a0Haschka\n                      : A.\u00a0Finanzielle Interessen: Sprecherhonorar: Alexion, Amgen, Gedeon Richter, Kyowa Kirin, UCB; Kongressunterst\u00fctzung: Accord, Amgen, Gedeon Richter, E.\u00a0Lilly, STADA, UCB. \u2013\u00a0Consultancy: Gedeon Richter, E.\u00a0Lilly.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellte Internistin\/Rheumatologin, Hanusch Krankenhaus, Wien; Research Group Leader, angestellt, Ludwig Boltzmann Institut f\u00fcr Ostelogie, Wien, angestellte Internistin\/Rheumatologin, Rheuma-Zentrum Wien Oberlaa | Vorstandsmitglied \u00d6sterr. Gesellschaft f\u00fcr Knochen und Mineralstoffwechsel, Vorstandsmitglied BioReg, Vorstandsmitglied \u00d6sterr. Gesellschaft f\u00fcr Endokrinologie und Stoffwechsel.","order":2,"name":"Ethics","label":"Autorinnen und Autoren","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":3,"name":"Ethics","label":"Wissenschaftliche Leitung","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":4,"name":"Ethics","label":"Der Verlag","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von der Autorin keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}